Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL27963055 | 0.96 | CA1 (0.46) | — | |
| Bicarbonate SCHEMBL2782263 | 0.96 | — | — | |
| Bicarbonate SCHEMBL2334734 | 0.92 | CA1 (0.42) | — | |
| Bicarbonate SCHEMBL21598431 | 0.92 | — | — | |
| Bicarbonate SCHEMBL4654017 | 0.92 | — | — | |
| Bicarbonate SCHEMBL4592112 | 0.92 | — | — | |
| Bicarbonate SCHEMBL7096240 | 0.92 | CA1 (0.42) | — | |
| Bicarbonate SCHEMBL15253751 | 0.92 | — | — | |
| Bicarbonate SCHEMBL5471870 | 0.92 | CA1 (0.42) | — | |
| Bicarbonate SCHEMBL27942113 | 0.92 | CA1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111875638-A | Preparation method of Reidesciclovir derivative, Reidesciclovir derivative and application thereof | 江苏省原子医学研究所 | 2020-11-03 | — | — | CN | disclosed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
| EP-1150952-B1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-10-27 | — | — | EP | disclosed |
| US-6737435-B1 | ANTIINFLAMMATORY AGENTS; MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) DISEASES | ASTRAZENECA AB (SE) | 2004-05-18 | — | — | US | disclosed |
| US-6573246-B1 | Anticancer agents | THE LIPOSOME COMPANY, INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1150952-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| US-6153736-A | ANTICANCER AGENTS | THE LIPOSOME COMPANY, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000046196-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |